Interacting Drugs |
Darunavir vs Calcium Channel Blockers (Nondihydropyridine) |
Security Level |
|
Mechanism |
Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. |
Management |
Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Use of ritonavir with bepridil is contraindicated. |
Darunavir vs Calcium Channel Blockers (Nondihydropyridine)
Post Review about Darunavir vs Calcium Channel Blockers (Nondihydropyridine) Click here to cancel reply.
Other Interactions of Darunavir
Other Interactions of Calcium Channel Blockers (Nondihydropyridine)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.